Regentis Biomaterials Ltd. has closed its initial public offering, raising $10 million through the sale of 1,250,000 ordinary shares at $8.00 per share. The company’s shares are now trading on the NYSE American LLC under the symbol “RGNT”. Proceeds from the offering will be used for development activities, including a pivotal trial for GerlinC. ThinkEquity acted as the sole book-running manager for the offering. Regentis is focused on developing orthopedic treatments using its Gelrin platform, with its lead product candidate, GelrinC, targeting painful injuries to articular knee cartilage. For more information, visit https://www.regentis.co.il/.

Read more at GlobeNewswire: Regentis Biomaterials Ltd. Announces Closing of Initial